Dr. Marty Makary has resigned as Commissioner of the Food and Drug Administration (FDA), concluding a tenure marked by internal strife and significant controversies. President Donald Trump announced the appointment of Kyle Diamantas, a former senior food official at the FDA, as the acting commissioner during a post on Truth Social. In his announcement, Trump characterized Makary as deserving of a successful future, despite the circumstances of his departure.
Makary’s resignation came after reports that the White House was considering his removal, a decision confirmed by a senior administration official. Health and Human Services Secretary Robert F. Kennedy Jr. was instrumental in this transition, and a new nominee for the permanent role is expected to be named in the coming weeks.
During his time at the FDA, Makary, a surgical oncologist, faced criticism for his handling of various issues, particularly around drug approvals. Stakeholders in the pharmaceutical industry expressed concern over his leadership style, especially following high-profile rejections of treatments for rare diseases and delays in the review of the abortion pill mifepristone. Makary’s approach to drug regulation had led to tensions with the pharmaceutical sector, particularly during negotiations over the Prescription Drug User Fee Act.
Furthermore, staff morale within the FDA reportedly declined due to layoffs and leadership changes initiated under Makary, including the departure of key personnel. Among these was Vinay Prasad, a controversial figure criticized for decisions related to vaccine approvals and treatment trials.
Trump’s nomination for a new commissioner will require Senate support, particularly from Sen. Bill Cassidy, a former physician who has previously indicated opposition to certain appointments within the Department of Health and Human Services.
Key Points:
- Why this story matters: The FDA’s leadership change could significantly impact drug regulation and approvals, influencing the pharmaceutical industry and public health policies.
- Key takeaway: Makary’s exit reflects ongoing tensions between the FDA and various stakeholders, including pharmaceutical companies and political figures.
- Opposing viewpoint: Supporters of Makary argue that his prioritization of rigorous drug approval processes was in the best interest of public safety, despite the controversies surrounding his decisions.
